Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 15/20 | 0.35 |
| ▸ | CA2 | P00918 | 15/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatine SCHEMBL8580872 | 0.89 | NOS3 (0.41) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL31156412 | 0.86 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4007614 | 0.86 | NOS3 (0.46) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL30063981 | 0.86 | — | — | |
| Creatine SCHEMBL21567 | 0.86 | — | — | |
| Creatine SCHEMBL27979093 | 0.86 | NOS3 (0.46) | NOS3NOS1NOS2CA1CA2 | |
| Cadaverine Tartrate SCHEMBL1286961 | 0.85 | NOS3 (0.47) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL5345184 | 0.84 | NOS3 (0.42) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL4269042 | 0.84 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 | |
| Creatine SCHEMBL21404054 | 0.84 | NOS3 (0.44) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | REGENTS OF THE UNIVERSITY OF NEBRASKA, BOARD OF | 2009-05-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137669-A1 | CREATINE ESTER ANTI-INFLAMMATORY COMPOUNDS AND FORMULATIONS | CKMT1A; CKMT1B, CPT1B, CRAT | NOS3 532/4885NOS1 572/4885NOS2 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.